Literature DB >> 20173352

Clinical usefulness of novel biomarkers for the detection of acute kidney injury following elective cardiac surgery.

Miaolin Che1, Bo Xie, Song Xue, Huili Dai, Jiaqi Qian, Zhaohui Ni, Jonas Axelsson, Yucheng Yan.   

Abstract

BACKGROUND/AIMS: Acute kidney injury (AKI) is common following cardiac surgery and predicts a poor outcome. However, the early detection of AKI has proved elusive and most cases are diagnosed only following a significant rise in serum creatinine (SCr). We compared a panel of early biomarkers of AKI for the detection of AKI in patients undergoing heart surgery. This study included serum cystatin C (CyC) and urinary levels of neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18 (IL-18), retinol-binding protein (RBP) and N-acetyl-beta-D-glucosaminidase (NAG).
METHODS: We retrospectively identified 15 patients undergoing open cardiac surgery who developed AKI within 72 h postoperatively. For these, we identified 15 matched controls also having undergone surgery but without AKI. Serial serum and urine samples had prospectively been postoperatively obtained from all patients at 0, 2, 4, 6, 10, 24, 48 and 72 h after admission to the intensive care unit. AKI was defined as a >50% increase in SCr. CyC was measured by nephelometry, while NGAL, IL-18, and RBP were measured by ELISA and NAG was measured by spectrophotometry. The urinary biomarkers were normalized to urinary creatinine (UCr) concentration. Each marker was assessed at each time point for its predictive value using receiver operating characteristic curves to predict AKI.
RESULTS: Following the exclusion of 1 case due to a urinary tract infection, the final cohort consisted of 29 patients aged 62.9 +/- 13.7 years with baseline SCr of 73.2 +/- 11.9 micromol/l. While there were no differences in the demographics between cases and controls, the aortic clamp time was predictably higher in AKI cases than in controls (60.6 +/- 13.9 vs. 43.0 +/- 9.2 min, p < 0.05). Each biomarker differed significantly between cases and controls for at least one time point. The optimal area under the curve (AUC) was for CyC at 10 h (sensitivity 0.71, specificity 0.92, cutoff 1.31 mg/l), NGAL at 0 h (sensitivity 0.84, specificity 0.80, cutoff 49.15 microg/g UCr), IL-18 at 2 h (sensitivity 0.85, specificity 0.73, cutoff 285.65 ng/g UCr), RBP at 0 h (sensitivity 0.75, specificity 0.67, cutoff 2,934.65 microg/g UCr) and NAG at 4 h (sensitivity 0.86, specificity 0.67, cutoff 37.05 U/mg UCr). Using a combination of all 5 biomarkers analyzed at the optimal time point as above, we were able to obtain an AUC of 0.98 (0.93-1.02, p < 0.001) in this limited sample.
CONCLUSION: The use of serum and urinary biomarkers for the prediction of AKI in patients undergoing cardiac surgery is highly dependent on the sampling time. Of the evaluated markers urinary NGAL had the best predictive profile. The previously unstudied marker of urinary RBP showed similar predictive power as more established markers. By combining all 5 studied biomarkers we were able to predict significantly more cases, suggesting that the use of more than one marker may be beneficial clinically.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20173352     DOI: 10.1159/000286352

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  22 in total

Review 1.  [Acute kidney injury after cardiac surgery : early diagnosis with neutrophil gelatinase-associated lipocalin].

Authors:  M Haase; A Haase-Fielitz
Journal:  Med Klin Intensivmed Notfmed       Date:  2011-10-29       Impact factor: 0.840

2.  Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B.

Authors:  Hong-Yu Jia; Feng Ding; Jian-Yang Chen; Jiang-Shan Lian; Yi-Min Zhang; Lin-Yan Zeng; Dai-Rong Xiang; Liang Yu; Jian-Hua Hu; Guo-Dong Yu; Huan Cai; Ying-Feng Lu; Lin Zheng; Lan-Juan Li; Yi-Da Yang
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 3.  Emergence of biomarkers in nephropharmacology.

Authors:  Enver Khan; Vecihi Batuman; Juan J L Lertora
Journal:  Biomark Med       Date:  2010-12       Impact factor: 2.851

Review 4.  The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer.

Authors:  Subhankar Chakraborty; Sukhwinder Kaur; Sushovan Guha; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2012-03-31

Review 5.  Role of biomarkers in the diagnosis and prognosis of acute kidney injury in patients with cardiorenal syndrome.

Authors:  Pam R Taub; Kelly C Borden; Arrash Fard; Alan Maisel
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-05

6.  Urinary biomarkers track the progression of nephropathy in hypertensive and obese rats.

Authors:  Qin Zhang; Kelly J Davis; Dana Hoffmann; Vishal S Vaidya; Ronald P Brown; Peter L Goering
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

7.  Rapid Detection of Acute Kidney Injury by Urinary Neutrophil Gelatinase-Associated Lipocalin in Patients Undergoing Cardiopulmonary Bypass.

Authors:  Muhammed Bayram; Mehmet Ezelsoy; Emrah Usta; Kerem Oral; Ayten Saraçoğlu; Zehra Bayramoğlu; Özgür Yıldırım
Journal:  Turk J Anaesthesiol Reanim       Date:  2014-07-09

Review 8.  Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status.

Authors:  Anja Haase-Fielitz; Michael Haase; Prasad Devarajan
Journal:  Ann Clin Biochem       Date:  2014-02-11       Impact factor: 2.057

9.  Role of new biomarkers: functional and structural damage.

Authors:  Evdoxia Tsigou; Vasiliki Psallida; Christos Demponeras; Eleni Boutzouka; George Baltopoulos
Journal:  Crit Care Res Pract       Date:  2013-02-05

10.  Serum and urine cystatin C are poor biomarkers for acute kidney injury and renal replacement therapy.

Authors:  Annick A N M Royakkers; Johanna C Korevaar; Jeroen D E van Suijlen; Lieuwe S Hofstra; Michael A Kuiper; Peter E Spronk; Marcus J Schultz; Catherine S C Bouman
Journal:  Intensive Care Med       Date:  2010-12-10       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.